Comparative Pharmacology
Head-to-head clinical analysis: MYCELEX versus VAGISTAT 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCELEX versus VAGISTAT 1.
MYCELEX vs VAGISTAT-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, thereby disrupting ergosterol biosynthesis and compromising fungal cell membrane integrity.
Tioconazole is an imidazole antifungal that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and fungal growth.
For oropharyngeal candidiasis: Clotrimazole troche 10 mg dissolved slowly in mouth 5 times daily for 14 days. For vulvovaginal candidiasis: Clotrimazole vaginal tablet 500 mg single dose or 200 mg daily for 3 days or 100 mg daily for 7 days; 1% vaginal cream 5 g intravaginally daily for 7-14 days.
One 300 mg vaginal suppository administered as a single dose.
None Documented
None Documented
Terminal elimination half-life is 20-50 hours (mean ~30 hours) in adults; prolonged in neonates (~40-80 hours) and in hepatic impairment.
The terminal elimination half-life is approximately 5-7 days, reflecting prolonged vaginal retention and slow systemic absorption.
Primarily hepatic metabolism; <1% excreted unchanged in urine; ~50% of dose excreted in feces as metabolites.
Approximately 50% is excreted unchanged in feces via biliary elimination; less than 1% is excreted unchanged in urine.
Category C
Category C
Azole Antifungal
Azole Antifungal